大分子生物分析技术市场规模 - 按产品、技术、应用、最终用途和预测，2024 年 - 2032 年

2024年至2032年，全球大分子生物分析技术市场的复合年增长率将达到10.4%。持续的技术进步提高了大分子分析的灵敏度和效率，满足生物製剂特性的复杂需求。增加研发投资、不断扩大的生物製品领域和持续创新的协同作用将推动市场发展，为全球製药、生物技术和研究领域提供关键解决方案。

例如，2024 年 1 月，安捷伦科技推出了 Agilent ProteoAnalyzer 系统，这是一个自动化 CE 平台。它简化并增强了复杂蛋白质混合物的分析，这对于製药、生物技术、食品分析和学术界等各个领域至关重要，从而优化了这些行业的分析工作流程。

大分子生物分析技术产业根据产品、技术、应用、最终用途和地区进行细分。

由于 CRO 的专业知识、先进技术以及开发和分析复杂生物製剂的简化流程，到 2032 年，合约研究组织部门将占据相当大的行业份额。随着製药和生物技术公司越来越多地外包其研发活动，CRO 成为关键合作伙伴，提供具有成本效益的解决方案并加快时间表。他们提供从临床前开发到临床试验的全面服务，使他们成为推动大分子生物分析领域创新和效率的关键参与者。

在这些革命性疗法的开发和采用激增的推动下，细胞和基因治疗领域的大分子生物分析技术市场将在 2032 年累积可观的效益。细胞和基因疗法需要复杂的生物分析工具来进行精确表征和监测，从而推动了对专业技术的需求。随着个人化医疗和生物技术的进步，细胞和基因治疗领域将经历大幅增长，巩固其作为大分子生物分析技术市场关键参与者的地位。

欧洲大分子生物分析技术产业规模从 2024 年到 2032 年将呈现惊人的复合年增长率，这得益于该地区强劲的製药和生物技术产业，培育了创新和研究文化。欧洲国家拥有许多专门从事大分子分析的生物製药公司和学术机构。此外，严格的监管框架和对尖端技术的投资也增强了欧洲在该市场的地位。欧洲致力于推动生物分析技术，将成为市场扩张的重要贡献者。

目录

第 1 章：方法与范围

第 2 章：执行摘要

第 3 章：产业洞察

• 产业生态系统分析
• 产业影响力
  • 成长动力
    • 对生物製剂和生物相似药的需求不断增加
    • 生物分析技术不断进步
    • 慢性病盛行率增加
    • 加强组学领域的研究与开发
  • 产业陷阱与挑战
    • 与这些技术相关的高成本
    • 缺乏标准化和验证
• 成长潜力分析
• 监管环境
• 技术景观
• 波特的分析
• PESTEL分析

第 4 章：竞争格局

• 介绍
• 公司市占率分析
• 竞争定位矩阵
• 战略展望矩阵

第 5 章：市场估计与预测：按产品划分，2018 年 - 2032 年

• 主要趋势
• 产品
  • 耗材及配件
  • 仪器
  • 试剂和试剂盒
• 服务

第 6 章：市场估计与预测：按技术划分，2018 年 - 2032 年

• 主要趋势
• 色谱法
• 质谱
• 酵素连结免疫吸附试验
• 电泳
• 聚合酶炼式反应
• 蛋白质印迹
• 流式细胞仪
• 光谱仪
• 其他技术

第 7 章：市场估计与预测：按应用划分，2018 年 - 2032 年

• 主要趋势
• 生物製剂
• 寡核苷酸衍生药物和分子
• 病毒载体
• 细胞与基因治疗
• 奈米粒子和聚合物
• 疾病诊断
• 其他应用

第 8 章：市场估计与预测：按最终用途，2018 - 2032 年

• 主要趋势
• 製药和生物技术公司
• 合约研究组织
• 研究与学术机构
• 其他最终用户

第 9 章：市场估计与预测：按地区划分，2018 年 - 2032 年

• 主要趋势
• 北美洲
  • 我们
  • 加拿大
• 欧洲
  • 德国
  • 英国
  • 法国
  • 义大利
  • 西班牙
  • 欧洲其他地区
• 亚太地区
  • 日本
  • 中国
  • 印度
  • 澳洲
  • 韩国
  • 亚太地区其他地区
• 拉丁美洲
  • 巴西
  • 墨西哥
  • 阿根廷
  • 拉丁美洲其他地区
• 中东和非洲
  • 沙乌地阿拉伯
  • 南非
  • 阿联酋
  • 中东和非洲其他地区

第 10 章：公司简介

• Bio-Rad Laboratories, Inc.
• Bio-Techne Corporation
• Cergentis B.V.
• Charles River Laboratories International, Inc.
• Danaher Corporation
• Halo Labs, Inc
• Intertek Group plc
• Laboratory Corporation of America Holdings
• Shizmandu Corporation
• SOLVIAS AG

Global Large Molecule Bioanalytical Technologies Market will record a 10.4% CAGR from 2024 to 2032. Rising R&D expenditure, particularly in biologics development, fuels the demand for advanced analytical tools. Ongoing technological advancements enhance the sensitivity and efficiency of large molecule analysis, catering to the complex needs of biologics characterization. This synergy of increased R&D investment, an expanding biologics landscape, and continuous innovation will propel the market, providing critical solutions for the pharmaceutical, biotech, and research sectors globally.

For instance, in January 2024, Agilent Technologies introduced the Agilent ProteoAnalyzer system, an automated CE platform. It streamlines and enhances the analysis of intricate protein mixtures, crucial in various sectors such as pharmaceuticals, biotech, food analysis, and academia, optimizing analytical workflows for these industries.

The large molecule bioanalytical technologies industry is segmented based on offering, technology, application, end use, and region.

The contract research organization segment will capture a considerable industry share by 2032 due to CROs' specialized expertise, advanced technologies, and streamlined processes for developing and analyzing complex biologics. As pharmaceutical and biotech companies increasingly outsource their research and development activities, CROs emerge as pivotal partners, offering cost-effective solutions and accelerated timelines. Their comprehensive services, spanning from preclinical development to clinical trials, position them as key players driving innovation and efficiency in the large molecule bioanalytical landscape.

The large molecule bioanalytical technologies market from the cell and gene therapy segment will accumulate substantial gains by 2032, fueled by the surge in the development and adoption of these revolutionary therapies. Cell and gene therapies necessitate intricate bioanalytical tools for precise characterization and monitoring, driving the demand for specialized technologies. With a focus on personalized medicine and advancements in biotechnology, the cell and gene therapy segment will experience substantial growth, solidifying its position as a key player in the large molecule bioanalytical technologies market.

Europe large molecule bioanalytical technologies industry size will exhibit a remarkable CAGR from 2024 to 2032, attributed to the region's robust pharmaceutical and biotechnology sectors, fostering a culture of innovation and research. European countries house numerous biopharmaceutical companies and academic institutions specializing in large molecule analysis. Additionally, stringent regulatory frameworks and investments in cutting-edge technologies bolster Europe's position in this market. With a commitment to advancing bioanalytical techniques, Europe will emerge as a substantial contributor to the market expansion.

Table of Contents

Chapter 1 Methodology & Scope

• 1.1 Market scope & definition
• 1.2 Base estimates & calculations
• 1.3 Data collection
• 1.4 Forecast parameters
• 1.5 Data validation
• 1.6 Data sources
  • 1.6.1 Primary
  • 1.6.2 Secondary
    • 1.6.2.1 Paid sources
    • 1.6.2.2 Public sources

Chapter 2 Executive Summary

• 2.1 Industry 360 degree synopsis

Chapter 3 Industry Insights

• 3.1 Industry ecosystem analysis
• 3.2 Industry impact forces
  • 3.2.1 Growth drivers
    • 3.2.1.1 Increasing demand for biologics & biosimilars
    • 3.2.1.2 Rising advancements in bioanalytical technology
    • 3.2.1.3 Increasing prevalence of chronic diseases
    • 3.2.1.4 Increasing research and development in the omics sector
  • 3.2.2 Industry pitfalls & challenges
    • 3.2.2.1 High costs associated with these technologies
    • 3.2.2.2 Lack of standardization and validation
• 3.3 Growth potential analysis
• 3.4 Regulatory landscape
• 3.5 Technological landscape
• 3.6 Porter's analysis
  • 3.6.1 Supplier power
  • 3.6.2 Buyer power
  • 3.6.3 Threat of new entrants
  • 3.6.4 Threat of substitutes
  • 3.6.5 Industry rivalry
• 3.7 PESTEL analysis

Chapter 4 Competitive Landscape, 2023

• 4.1 Introduction
• 4.2 Company market share analysis
• 4.3 Competitive positioning matrix
• 4.4 Strategy outlook matrix

Chapter 5 Market Estimates and Forecast, By Offering, 2018 - 2032 ($ Mn)

• 5.1 Key trends
• 5.2 Products
  • 5.2.1 Consumables & accessories
  • 5.2.2 Instruments
  • 5.2.3 Reagents & kits
• 5.3 Service

Chapter 6 Market Estimates and Forecast, By Technology, 2018 - 2032 ($ Mn)

• 6.1 Key trends
• 6.2 Chromatography
• 6.3 Mass spectrometry
• 6.4 ELISA
• 6.5 Electrophoresis
• 6.6 Polymerase chain reaction
• 6.7 Western blot
• 6.8 Flow cytometry
• 6.9 Spectrometer
• 6.10 Other technologies

Chapter 7 Market Estimates and Forecast, By Application, 2018 - 2032 ($ Mn)

• 7.1 Key trends
• 7.2 Biologics
• 7.3 Oligonucleotide derived drugs & molecules
• 7.4 Viral vector
• 7.5 Cell & gene therapy
• 7.6 Nanoparticles & polymers
• 7.7 Disease diagnosis
• 7.8 Other applications

Chapter 8 Market Estimates and Forecast, By End-Use, 2018 - 2032 ($ Mn)

• 8.1 Key trends
• 8.2 Pharmaceutical & biotechnology companies
• 8.3 Contract research organizations
• 8.4 Research & academic institutes
• 8.5 Other end-users

Chapter 9 Market Estimates and Forecast, By Region, 2018 - 2032 ($ Mn)

• 9.1 Key trends
• 9.2 North America
  • 9.2.1 U.S.
  • 9.2.2 Canada
• 9.3 Europe
  • 9.3.1 Germany
  • 9.3.2 UK
  • 9.3.3 France
  • 9.3.4 Italy
  • 9.3.5 Spain
  • 9.3.6 Rest of Europe
• 9.4 Asia Pacific
  • 9.4.1 Japan
  • 9.4.2 China
  • 9.4.3 India
  • 9.4.4 Australia
  • 9.4.5 South Korea
  • 9.4.6 Rest of Asia Pacific
• 9.5 Latin America
  • 9.5.1 Brazil
  • 9.5.2 Mexico
  • 9.5.3 Argentina
  • 9.5.4 Rest of Latin America
• 9.6 Middle East and Africa
  • 9.6.1 Saudi Arabia
  • 9.6.2 South Africa
  • 9.6.3 UAE
  • 9.6.4 Rest of Middle East and Africa

Chapter 10 Company Profiles

• 10.1 Bio-Rad Laboratories, Inc.
• 10.2 Bio-Techne Corporation
• 10.3 Cergentis B.V.
• 10.4 Charles River Laboratories International, Inc.
• 10.5 Danaher Corporation
• 10.6 Halo Labs, Inc
• 10.7 Intertek Group plc
• 10.8 Laboratory Corporation of America Holdings
• 10.9 Shizmandu Corporation
• 10.10 SOLVIAS AG